In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Genmab (GMAB), with a price target of $37.00. The company’s shares closed last Thursday at $39.51.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 18.1% and a 62.1% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Freeline Therapeutics Holdings, and Global Blood Therapeutics.
Currently, the analyst consensus on Genmab is a Moderate Buy with an average price target of $39.50, which is a -0.3% downside from current levels. In a report released today, RBC Capital also maintained a Buy rating on the stock with a DKK40.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $38.87 and a one-year low of $16.24. Currently, Genmab has an average volume of 551.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its portfolio includes two products, daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.
